CHICAGO, ILLINOIS--(Marketwire - June 03, 2008) - MethylGene Inc. (TSX: MYG) today announced preliminary data from a Phase II clinical study evaluating MGCD0103, a novel, isoform-selective histone deacetylase (HDAC) inhibitor, in relapsed or refractory non-Hodgkin lymphomas (Trial 008). Results from this single-agent trial, conducted in collaboration with Celgene Corporation and Taiho Pharmaceutical, were presented today at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.